Current Report Filing (8-k)
February 22 2017 - 4:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
February
22, 2017
Clovis
Oncology, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-35347
|
90-0475355
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
5500 Flatiron Parkway, Suite 100
Boulder, Colorado
|
|
80301
|
|
|
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(303) 625-5000
Not
Applicable
(Former name or former address, if changed since last
report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02
|
Results of Operations and Financial Condition
|
On February 22, 2017, Clovis Oncology, Inc. (the “Company”) issued a
press release announcing its financial results for the quarter and year
ended December 31, 2016. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 of Form 8-K and the information
incorporated by reference herein, including Exhibit 99.1 attached
hereto, shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933
or the Exchange Act, except as expressly set forth by specific reference
in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
Number and Description
99.1
|
Press Release, dated February 22, 2017.
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
CLOVIS ONCOLOGY, INC.
|
|
|
|
February 22, 2017
|
|
By:
|
/s/ Patrick J. Mahaffy
|
|
|
Name:
|
Patrick J. Mahaffy
|
|
|
Title:
|
President and Chief Executive Officer
|
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated February 22, 2017.
|
- 4 -
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Apr 2023 to Apr 2024